Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Dec 14, 2021; 27(46): 8010-8030
Published online Dec 14, 2021. doi: 10.3748/wjg.v27.i46.8010
Table 3 Profiles of metachronous multiple remnant gastric cancer patients
No.
Group
ISP
Treatment
MTMC
Curability1
MRSC
PROG2
1SNNSSGDG50.5Curative75.6Pneumonia
2SNNSSGESD60.2Curative114.9Alive
3SNNSSGESD22.9Curative79.9Alive
4SNNSMPGESD13.6Curative76.3Alive
5SNNSLRESD30.7Curative73.1Alive
6SNNSDGTG43.6Curative62.9Alive
7ControlDGTG19.5Curative63.6Alive
8ControlDGTG17.2Curative97.4Alive
9ControlDGESD44.3Curative55.5AID
10ControlDGESD220.4Curative240.0Alive
11ControlDGESD40.6Curative120.0Alive
12ControlPGUR74.3UR120.0Alive
13ControlPGTG76.8Curative120.0Alive
14ControlPGESD18.5Curative120.0Alive
15ControlPGESD28.2Curative120.0Alive
16ControlPPGTG50.8Curative120.0Alive
17ControlPPGDG85.0Curative116.2Alive
18ControlPPGESD77.1Curative118.5Alive
19ControlPPGESD22.0Curative98.2Alive
20ControlLRDG7.6Cure42.8CVD
21ControlLRESD64.2Cure85.7Alive